UK-based startup Oyster Therapeutics has raised $60 million in first-round financing that will be used to advance its tau ...

The FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to the label of their products for a rare eye ...

Just a few months after being formed, China's Funnel Biosciences has signed a $2 billion-plus partnership with Third Rock ...

Asundexian has been approved by the FDA under the Sunharbo brand name for use in combination with antiplatelet therapy to ...

Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...

Notably, raising growth capital and strategic partnering remain the most common planned activities, while relatively few respondents anticipate pursuing M&A specifically, a distinction worth holding ...

The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...

More than ever, pharma firms are under increasing pressure to harness the power of AI, advanced analytics, and machine ...

Amazon Web Services (AWS) has committed $100 million in AI and cloud technology capacity to support the building of health ...

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

The comprehensive failure of Lp (a)HORIZON has cast a pall over the prospects for other Lp (a)-targeting drugs, including Amgen's olpasiran and Eli Lilly's lepodisiran, two similarly-acting ...